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Abstract
Introduction: Tumefactive multiple sclerosis is a demyelinating disease that demonstrates tumor-like features on
magnetic resonance imaging. Although diagnostic challenges without biopsy have been tried by employing
radiological studies and cerebrospinal fluid examinations, histological investigation is still necessary for certain
diagnosis in some complicated cases.
Case presentation: A 37-year-old Asian man complaining of mild left leg motor weakness visited our clinic.
Magnetic resonance imaging demonstrated high-signal lesions in bilateral occipital forceps majors, the left caudate
head, and the left semicentral ovale on fluid-attenuated inversion recovery and T2-weighted imaging, and these
lesions were enhanced by gadolinium-dimeglumin. Tumefactive multiple sclerosis was suspected because the
enhancement indistinctly extended along the corpus callosum on magnetic resonance imaging and scintigraphy
showed a low malignancy of the lesions. But oligoclonal bands were not detected in cerebrospinal fluid. In a few
days, his symptoms fulminantly deteriorated with mental confusion and left hemiparesis, and steroid pulse therapy
was performed. In spite of the treatment, follow-up magnetic resonance imaging showed enlargement of the
lesions. Therefore, emergent biopsy was performed and finally led to the diagnosis of demyelinating disease. The
enhanced lesion on magnetic resonance imaging disappeared after one month of prednisolone treatment, but
mild disorientation and left hemiparesis remained as sequelae.
Conclusions: Fulminant aggravation of the disease can cause irreversible neurological deficits. Thus, an early
decision to perform a biopsy is necessary for exact diagnosis and appropriate treatment if radiological studies and
cerebrospinal fluid examinations cannot rule out the possibility of brain tumors.
Introduction
Tumefactive multiple sclerosis (tMS) is a demyelinating
disease. Because of its tumor-like features on magnetic
resonance imaging (MRI) [1,2], histological investigation
had played an important role for definite diagnosis of
tMS [3,4]. Recently, without biopsy, some tMS cases
were diagnosed by magnetic resonance spectroscopy
(MRS), positron emission tomography (PET), cerebrosp-
inal fluid (CSF) examination, and response to steroid
treatment [5-9]. However, the diagnosis of tMS without
histological confirmation is no more than speculation in
some complicated cases. We report the case of a patient
who had tMS and who required emergent biopsy for
exact diagnosis because of rapid enlargement of lesions
on MRI after steroid pulse therapy.
Case presentation
A 37-year-old Asian man who complained of a two-
month history of dizziness visited our clinic. Neurologi-
cal examinations using the manual muscle test revealed
a left leg motor weakness of 5-/5 on the Medical
Research Council (MRC) scale [10,11]. MRI demon-
strated high-signal lesions in bilateral occipital forceps
majors, the left caudate head, and the left semicentral
ovale on both fluid-attenuated inversion recovery
(FLAIR) and T2-weighted (T2W) imaging (Figure 1,
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nium-dimeglumin with expansion along the corpus cal-
losum (Figure 1, lower frame). But these enhancements
were not as strong as those recognized in malignant
brain tumors. Definite uptake of thallium was identified
by
201Tl scintigraphy in both early and delay phases.
However, the retention index (ratio of thallium uptake
between delay and early phases) was 0.88, which was
too low for malignant brain tumors to be suspected
(Figure 2). tMS was suspected on the basis of the obser-
vations of MRI and scintigraphy. However, oligoclonal
bands were not detected by CSF examinations. For
further investigation, MRS and PET were planned for
our patient.
A few days later, he was admitted to our hospital
because of progression of his left leg motor weakness (4
+/5 on the MRC scale). The day after admission, he
exhibited mental confusion and left hemiparesis (2/5 on
the MRC scale), and three-day consecutive steroid pulse
therapy (1000 mg of methylprednisolone sodium succi-
nate and 8 mg of dexamethasone per day) was applied.
Despite the treatment, his symptoms did not improve,
and MRI showed further enlargement of the lesions
(Figure 3). Therefore, without MRS and PET studies, an
emergent open biopsy under a navigation system was
performed for definite diagnosis.
Histological investigation showed perivascular prolif-
eration of lymphocytes without atypical features, and
Kluver-Barrera staining displayed sporadic absence of
the myelin sheath, suggesting demyelinating disease
(Figure 4a-c). The majority of the proliferating lympho-
cytes were T-cell type (Figure 4d), and the existence of
lymphocytes positive for both cluster of differentiation
(CD) 4 and CD8 (Figures 4e and 4f) ruled out monoclo-
nal increase of the lymphocytes. Furthermore, the pre-
sence of macrophages (CD68) strongly implied
inflammatory changes in the lesion (Figure 4g). After
one month of prednisolone treatment, MRI revealed
remarkable shrinking of the lesions (Figure 5), but mild
disorientation and left hemiparesis (4+/5 on the MRC
scale) remained as sequelae.
Discussion
The term ‘tumefactive MS’ is used when the clinical
presentation and MRI findings are indistinguishable
Figure 1 Pre-operative magnetic resonance imaging.H i g h -
intensity areas in bilateral occipital forceps majors, the left caudate
head, and the left semicentral ovale are shown in both fluid-
attenuated inversion recovery (FLAIR) and T2-weighted (T2W)
imaging. These lesions are enhanced indistinctly by gadolinium-
dimeglumin (Gd).
Figure 2 Uptake of thallium in the lesions on
201Tl
scintigraphy. Definite uptake of thallium is identified in the lesions.
However, the retention index (ratio of thallium uptake between late
and early phases) is 0.88, suggesting a low possibility of malignancy.
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Page 2 of 4Figure 3 Magnetic resonance imaging after steroid pulse
therapy. High-intensity areas in the left caudate head, bilateral
semicentral ovales, and bilateral occipital forceps majors are clearly
enlarged on FLAIR and T2W imaging. Gd-enhanced lesions in the
occipital forceps majors are clearly expanded.
Figure 4 Definite diagnosis of tMS by histological investigations. Histology shows proliferation of lymphocytes (arrowheads) without
atypical features by hematoxylin-eosin (HE) staining (a). Kluver-Barrera staining demonstrates sporadic defects of myelin (arrows), indicating
demyelinations (b). Perivascular lymphocyte proliferation is recognized by HE staining (c). These lymphocytes are composed mainly of CD3-
positive T-cell lymphocytes (d), and a mixture of CD4-positive (e) and CD8-positive (f) T-cell lymphocytes rules out monoclonal increase of the
lymphocytes. The appearance of macrophages (CD68) in the lesion strongly suggests inflammatory disease (g) rather than malignant lymphoma.
CD: cluster of differentiation.
Figure 5 MRI after one month of steroid therapy. High-intensity
areas in (FLAIR) and T2W imaging considerably shrink and Gd-
enhanced lesions completely disappear after one month of steroid
treatment. Arrows show the point of biopsy.
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cessful challenges to diagnose tMS by using MRS and
PET, without biopsy, have been reported [5-7], and care-
ful follow-up by serial MRI with or without steroid
treatment is usually sufficient to establish the diagnosis.
In general, tMS lesions respond well to steroids and no
radiological evidence of new lesions is identified after
the treatment in most patients [13]. Although the clini-
cal course of tMS is various with acute onset, the prog-
nosis of tMS usually does not depend on the clinical
presentation [3]. However, in some atypical cases, the
radiological diagnosis is no more than speculative if his-
tological diagnosis is not obtained. Butteriss and collea-
gues [14] reported an interesting case of
oligodendroglioma in MS that was diagnosed by surgical
removal of the lesion but that had been considered to
be tMS on pre-operative MRI. In our case, fulminant
deterioration of the clinical symptoms and rapid enlar-
gement of the lesions on MRI in spite of steroid pulse
therapy confounded the diagnosis of tMS. When mono-
clonal bands are not detected in CSF and radiological
examinations cannot completely rule out a malignant
brain tumor, an early decision to perform a biopsy is
required. Once fulminant deterioration of clinical signs
and symptoms occurs in a patient with tMS, the neuro-
logical deficits can be irreversible.
Conclusions
To diagnose tMS without histological investigation is an
initial approach to the disease. However, early biopsy
should not be delayed if radiological examination failed
to confirm the diagnosis.
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